Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Swiss National Bank

Swiss National Bank decreased its position in Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating) by 0.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 159,554 shares of the medical equipment provider’s stock after selling 500 shares during the quarter. Swiss National Bank’s holdings in Lantheus were worth $10,535,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Dupont Capital Management Corp purchased a new stake in shares of Lantheus during the second quarter valued at $32,000. Veriti Management LLC purchased a new stake in shares of Lantheus during the second quarter valued at $205,000. State of Tennessee Treasury Department lifted its holdings in shares of Lantheus by 9.5% during the first quarter. State of Tennessee Treasury Department now owns 44,248 shares of the medical equipment provider’s stock valued at $2,447,000 after purchasing an additional 3,853 shares during the last quarter. Banque Cantonale Vaudoise purchased a new stake in shares of Lantheus during the second quarter valued at $417,000. Finally, Range Financial Group LLC purchased a new stake in shares of Lantheus during the second quarter valued at $553,000. Institutional investors and hedge funds own 98.14% of the company’s stock.

Lantheus Stock Performance

Shares of LNTH stock opened at $57.70 on Monday. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.13 and a quick ratio of 1.98. Lantheus Holdings, Inc. has a fifty-two week low of $23.51 and a fifty-two week high of $87.47. The stock’s 50-day moving average is $69.50 and its two-hundred day moving average is $70.33. The firm has a market cap of $3.97 billion, a P/E ratio of 38.72 and a beta of 0.79.

Lantheus (NASDAQ:LNTHGet Rating) last issued its earnings results on Thursday, November 3rd. The medical equipment provider reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.15. Lantheus had a return on equity of 37.77% and a net margin of 13.35%. The company had revenue of $239.29 million for the quarter, compared to analyst estimates of $228.52 million. Analysts predict that Lantheus Holdings, Inc. will post 3.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on LNTH. Jonestrading began coverage on Lantheus in a report on Thursday, October 6th. They set a “buy” rating and a $104.00 target price for the company. Mizuho assumed coverage on Lantheus in a research note on Wednesday, October 12th. They issued a “buy” rating and a $105.00 price objective for the company. B. Riley reissued a “buy” rating on shares of Lantheus in a research note on Thursday, August 25th. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research note on Friday, November 4th. Finally, SVB Leerink increased their price objective on Lantheus from $110.00 to $120.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 15th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lantheus currently has an average rating of “Buy” and an average target price of $102.80.

Insiders Place Their Bets

In other news, CEO Mary Anne Heino sold 13,150 shares of the stock in a transaction dated Tuesday, November 8th. The stock was sold at an average price of $57.21, for a total transaction of $752,311.50. Following the transaction, the chief executive officer now owns 672,533 shares of the company’s stock, valued at approximately $38,475,612.93. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CEO Mary Anne Heino sold 13,150 shares of the stock in a transaction dated Tuesday, November 8th. The stock was sold at an average price of $57.21, for a total transaction of $752,311.50. Following the transaction, the chief executive officer now owns 672,533 shares of the company’s stock, valued at approximately $38,475,612.93. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Andrea Sabens sold 386 shares of the stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $85.83, for a total value of $33,130.38. Following the transaction, the chief accounting officer now directly owns 62,390 shares in the company, valued at approximately $5,354,933.70. The disclosure for this sale can be found here. Insiders have sold a total of 66,098 shares of company stock valued at $5,054,679 in the last three months. Insiders own 1.60% of the company’s stock.

About Lantheus

(Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Featured Articles

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.